COMMUNIQUÉS West-GlobeNewswire

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business
28/04/2025
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and [...]
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
28/04/2025
EMA designation provides orphan status to medicines being developed for rare conditions that are intended for the diagnosis, prevention or treatment of diseases affecting fewer than 5 in 10,000 people in the European [...]
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland
28/04/2025
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland London, 28 April 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
28/04/2025
VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical [...]
BioVersys to Host Virtual KOL Event to Discuss BV100 Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter on May 7, 2025
28/04/2025
Event titled “ BV100 Shows Survival Benefit in Phase 2 Ventilator Associated Pneumonia (VABP) Study Against Carbapenem Resistant Acinetobacter. What Does that Mean for Patients? A Perspective from the US and from Asia [...]
Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test
27/04/2025
Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNA Genes include key targets for next generation precision medicines, such as NECTIN4, B7H4, HER3 [...]
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
27/04/2025
NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
27/04/2025
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2 [...]
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
27/04/2025
Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer REDWOOD [...]
Mitolyn Reviews: DO NOT Spend A Dime Until You’ve Read This Report?
27/04/2025
The weight loss revolution : Mitolyn's Mitochondrial Mastery System Delivers Sustainable Fat Burning Together with Increased Energy Levels Albany, New York, April 27, 2025 (GLOBE NEWSWIRE) -- Various weight loss [...]
SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union
27/04/2025
STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the [...]
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
27/04/2025
Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a [...]
Best Male Enhancement Pills & Libido Booster For Men: (Penis Enlargement Pills) Over The Counter Best ED Pills Non Prescription – By Performer 8
27/04/2025
More than 50% of men now face erectile dysfunction after the age of 40. In a few cases, men in their 20s and 30s face a similar situation. You can find here the Best Male Enhancement Pills & Libido Booster for Men ( [...]
2025 (Spring) Pharmaceutical Machinery Exposition Concludes Successfully
27/04/2025
BEIJING, April 27, 2025 (GLOBE NEWSWIRE) -- On April 25, 2025, the 66th (Spring 2025) National Pharmaceutical Machinery Exposition & 2025 (Spring) China International Pharmaceutical Machinery Exposition (hereinafter [...]
Best Legal Steroids For Muscle Growth: Top Anabolic Steroids Alternatives For (Bulking & Bodybuilding) That Really Work – By Crazy Bulk
27/04/2025
After six months of research on the ingredients and thousands of feedback from real consumers, we can safely say that legal steroids are 100% legal and they do work for bulking and bodybuilding. New York City, April 26 [...]
Three-Year Data of Zenflow’s Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH
26/04/2025
Data Presented at the AUA Meeting Reflect Longest-Term Data among FIT Interventions SOUTH SAN FRANCISCO, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc. announced today the results of long-term data [...]
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
26/04/2025
- Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – - 58.3% of patients showed durable complete responses by K-M at 24 months – - 97.3% of all treated patients [...]
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
26/04/2025
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one [...]
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
26/04/2025
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical [...]

Pages